FDA staff says BiDil cuts deaths among black heart patients

06/16/2005 | Reuters

An FDA staff analysis says NitroMed's heart-failure drug BiDil significantly reduced deaths and hospitalizations among blacks in a clinical study, and it should be indicated for treatment of black patients. The staff report was released in advance of today's FDA advisory panel meeting to decide if BiDil should become the first drug approved for treatment of a specific racial group.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA